# Sunday 8 November 2026

| | | |
|---|---|---|
| **13:00–13:45** | **Lunch, Exhibition and Scientific Posters** | **Hall 4** |
| **13:45–15:15** | **STEPS 12: The Giulio Maria Corbelli Workshop – A Community Initiative to Design the Pathway to a Durable ART-Free Control of HIV Infection**<br>*A workshop organised by the European AIDS Treatment Group (EATG)* | Clyde |
| **Chair** | **Giorgio Barbareschi,** *European AIDS Treatment Group (EATG)*<br>**Sean Hosein,** *Science and Medicine Editor, Canadian AIDS Treatment Information Exchange (CATIE) and EATG, Toronto, Canada* | |
| 13:45–13:50 | **Welcome note and introduction to the programme**<br>**Sean Hosein** | |
| 13:50–14:00 | **An introduction to the EU2Control Platform**<br>**Casper Rokx,** *Internal Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands* | |
| 14:00–14:10 | **A summary of selected approaches in HIV cure research**<br>**Mark Janse,** *Infectious Diseases, Erasmus Medical Center, Rotterdam, The Netherlands* | |
| 14:10–14:20 | **HIV trial platform and CAR-T**<br>**Marius Trøseid,** *Oslo University Hospital, Oslo, Norway* | |
| 14:20–14:30 | **What can we learn from pregnancy and the fetus about HIV cure?**<br>**Marion Pardons,** *Charité Universitätsmedizin, Berlin, Germany* | |
| 14:30–14:40 | **Why studying quality of life of people in HIV cure research is important**<br>**Kevin Moody,** *Academic Medical Centre, Amsterdam, The Netherlands* | |
| 14:40–14:50 | **The IDUNN clinical trial**<br>**Ole Schmeltz Søgaard,** *Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark* | |
| 14:50–15:00 | **Engaging with the community**<br>**Tomer Einav,** *BeCURE – Berlin Centre for HIV Cure Research, Charité, Berlin, Germany* | |
| 15:00–15:15 | **Discussion**<br>**All** | |
| **15:15–15:45** | **Coffee, Exhibition and Scientific Posters** | **Hall 4** |
| **15:45–17:00** | **Industry Symposium** | **Clyde** |
| **17:00–17:30** | **Coffee, Exhibition and Scientific Posters** | **Hall 4** |
| **17:30–17:50** | **Official Opening** | **Clyde** |
| 17:30–17:45 | **Welcome to the Congress**<br>**Alexandra Calmy,** *University of Geneva, Geneva, Switzerland*<br>**Chloe Orkin,** *Queen Mary University of London, and Barts Health NHS Trust, London, UK* | |
| 17:45–17:50 | **Welcome from Glasgow City**<br>**Bailie Martha Wardrop,** *representative from Lord Provost's Office, Glasgow, UK* | |

## Sunday 8 November 2026

| | | |
|---|---|---|
| **17:50–19:00** | **From Confusion to Clarity: Addressing Health Misinformation at Scale** | **Clyde** |
| **Co-chairs** | **Alexandra Calmy**<br>**Chloe Orkin** | |
| 17:50–17:55 | **Welcome and introduction**<br>**Chloe Orkin** | |
| 17:55–18:10 | **What do we do about scientific confusion vs vaccine mistrust?**<br>**Boghuma Titanji,** *Department of Medicine, Emory University, Atlanta, GA, USA* | |
| 18:10–18:35 | **Misinformation and disinformation, definitions, how it manifests on social media, AI algorithms when it comes from a public health official source**<br>**Kai Kupferschmidt,** *Science Magazine, Berlin, Germany* | |
| 18:35–19:00 | **Panel discussion, Q&A and close**<br>**All** | |
| **19:00–19:45** | **Civic Reception**<br>*HIV Glasgow 2026 gratefully acknowledges the civic hospitality of the Lord Provost of Glasgow and Glasgow City Council* | **Hall 4** |

# Monday 9 November 2026

| | | |
|---|---|---|
| **08:30–09:30** | **Industry Symposium** | **Clyde** |
| **09:30–10:00** | **Coffee, Exhibition and Scientific Posters** | **Hall 4** |
| 10:00–11:30 | **PrEP Today and Tomorrow: Challenges, Advances and Equitable Access** | **Clyde** |
| **Co-chairs** | **Justyna Kowalska,** *Hospital for Infectious Diseases in Warsaw, Warsaw, Poland*<br>**Davide Moschese,** *Università degli Studi di Milano, Milan, Italy* | |
| 10:00–10:05 | **Welcome and introduction**<br>***Justyna Kowalska*** | |
| 10:05–10:20 | **Current PrEP and complex management**<br>**Jade Ghosn,** *Infectious Diseases and Sexual Health Clinic, Bichat University Hospital and Université Paris Cité School of Medicine, Paris, France* | |
| 10:20–10:35 | **What's the future of PrEP, talking about once-monthly oral and longer duration injectables and the pipeline, including access**<br>**Lobna Gayeeb,** *Medicines Patent Pool – MPP, Geneva, Switzerland* | |
| 10:35–10:50 | **PrEP use in key groups**<br>**Yevheniia Rudhenka,** *100% Life, Ukraine* | |
| 10:50–10:58 | **O21: Higher persistence on twice-yearly lenacapavir versus daily F/TDF for PrEP in the UK and France in the PURPOSE 5 study**<br>**Chloe Orkin,** *Queen Mary University of London, and Barts Health NHS Trust, London, UK* | |
| 10:58–11:06 | **O22: Mind the gap: estimating the impact of HIV PrEP on the epidemic in Switzerland**<br>**Benjamin Hampel,** *Department of Public and Global Health University of Zurich, Zurich, Switzerland* | |
| 11:06–11:30 | **Q&A and close**<br>**All faculty including oral presenters** | |
| **11:30–12:15** | **Keynote Lecture: The Evolving Cure Landscape**<br>*Lock Lecture gifted by the Royal College of Physicians and Surgeons of Glasgow* | **Clyde** |
| **Chair** | **Daniel Kuritzkes,** *Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA* | |
| 11:30–11:35 | **Welcome and introduction**<br>**Daniel Kuritzkes** | |
| 11:35–12:05 | **What's happening in the cure space?**<br>**Ole Schmeltz Søgaard,** *Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark* | |
| 12:05–12:15 | **Q&A and close** | |
| **12:15–13:45** | **Lunch, Exhibition and Scientific Posters** | **Hall 4** |
| **12:30–13:30** | **Industry Symposium** | **Clyde** |

# Monday 9 November 2026

| | | |
|---|---|---|
| **13:45–15:00** | **Clinical Case Studies**<br>*In collaboration with www.hiv-druginteractions.org* | **Clyde** |
| **Facilitators** | **Saye Khoo,** *Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK*<br>**Catia Marzolini,** *University Hospital Lausanne, Lausanne, Switzerland, and University of Liverpool, Liverpool, UK*<br>**Fiona Marra,** *University of Liverpool, Liverpool, UK* | |
| **Discussants** | **Juan Ambrosioni,** *HIV Unit, Infectious Disease Service, Hospital Clinic-IDIBAPS, Barcelona, Spain*<br>**Susanne Dam Nielsen,** *Infectious Diseases, Copenhagen University Hospital – Rigshospitalet, Copenhagen, Denmark*<br>**Karine Lacombe,** *Hôpital Saint Antoine, Paris, France* | |
| 13:45–13:50 | **Welcome and introduction**<br>Saye Khoo | |
| 13:50–14:10 | **Case 1: PrEP**<br>**Facilitator: Catia Marzolini**<br>**Case Presenters: Simon Collins,** *HIV i-Base, London, UK*<br>**Benjamin Hampel,** *Department of Public and Global Health, University of Zurich, Zurich, Switzerland* | |
| 14:10–14:30 | **Case 2: INSTI vs boosted PI**<br>**Facilitator: Saye Khoo**<br>**Case Presenter: Marta Boffito,** *Chelsea and Westminster Hospital NHS Foundation Trust, London, UK* | |
| 14:30–14:50 | **Case 3: HIV coinfection with HEP B +/- HEP D**<br>**Facilitator: Fiona Marra**<br>**Case Presenter: Christoph Boesecke,** *Bonn University Hospital, Bonn, Germany* | |
| 14:50–15:00 | **Closing remarks**<br>**Saye Khoo** | |
| **15:00–16:15** | **STIs and HPV in People with HIV: Current Perspectives and Emerging Solutions** | **Clyde** |
| **Co-chairs** | **Magdalena Ankiersztejn-Bartczak,** *Foundation for Social Education, Warsaw, Poland*<br>**Bernard Surial,** *Department of Infectious Diseases, Inselspital, University Hospital Bern, Switzerland* | |
| 15:00–15:05 | **Welcome and introduction**<br>**Bernard Surial** | |
| 15:05–15:15 | **To treat or not to treat (all diagnosed STIs)? – that is the question**<br>**Michael Rayment,** *Sexual Health and HIV, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK* | |
| 15:15–15:25 | **New antibiotics for gonorrhoea**<br>**Chris Kenyon,** *Institute of Tropical Medicine Antwerp, Antwerp, Belgium, and University of Cape Town, Cape Town, South Africa* | |
| 15:25–15:35 | **Rounding up the evidence around a single dose for HPV – is that OK for people with HIV?**<br>**Deborah Konopnicki,** *Infectious Diseases, Saint-Pierre University Hospital, Brussels, Belgium* | |
| 15:35–15:45 | **Elimination of cervical cancer in Australia and Denmark and Global inequity**<br>**Mark O'Reilly,** *East Sydney Doctors and Taylor Square Private Clinic, Darlinghurst, NSW, Australia* | |
| 15:45–16:15 | **Q&A and closing remarks**<br>**All** | |

# Monday 9 November 2026

| | | |
|---|---|---|
| 16:15–16:40 | **Keynote Lecture: Hidden in Plain Sight: Why Advanced HIV Disease Demands Attention** | **Clyde** |
| **Chair** | **Iskandar Azwa,** *Infectious Diseases Unit, Faculty of Medicine, University Malaya, Kuala Lumpur, Malaysia* | |
| 16:15–16:18 | **Welcome and introduction**<br>**Iskandar Azwa** | |
| 16:18–16:40 | **Why Advanced HIV Disease Demands Attention**<br>**Ajay Rangaraj,** *Department of HIV, TB, Hepatitis and STIs, World Health Organization, Geneva, Switzerland* | |
| 16:40–17:50 | **EACS Guidelines Session: 2026 Update**<br>*In collaboration with the European AIDS Clinical Society (EACS)* | **Clyde** |
| **Co-chairs** | **Jasmini Alagaratnam,** *HIV Medicine, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK*<br>**Juan Ambrosioni,** *HIV Unit, Infectious Disease Service, Hospital Clinic-IDIBAPS, Barcelona, Spain*<br>**Jürgen Rockstroh,** *HIV Outpatient Clinic, University of Bonn, Bonn, Germany* | |
| 16:40–16:45 | **Welcome and introduction**<br>**Juan Ambrosioni** | |
| 16:45–16:55 | **Antiretroviral treatment and prevention**<br>**Annalisa Marinosci,** *University Hospital of Geneva, Geneva, Switzerland* | |
| 16:55–17:05 | **Co-infections**<br>**Andrea Mastrangelo,** *Centre Hospitalier Universitaire Vaudoise – CHUV, Lausanne, Switzerland* | |
| 17:05–17:15 | **Paediatric HIV**<br>**Paolo Paioni,** *Division of Infectious Diseases and Hospital Epidemiology, University Children's Hospital Zurich, Zurich, Switzerland* | |
| 17:15–17:30 | **Co-morbidities**<br>**Abiu Sempere,** *Hospital Clinic of Barcelona, Barcelona, Spain*<br>**Moisés Alberto Suárez-Zdunek,** *Infectious Diseases, Copenhagen University Hospital – Rigshospitalet, Copenhagen, Denmark* | |
| 17:30–17:50 | **Q&A, panel discussion and close**<br>**Alasdair Bamford,** *Great Ormond Street Hospital, London, UK*<br>**Alexandra Calmy,** *University of Geneva, Geneva, Switzerland*<br>**Susanne Dam Nielsen,** *Infectious Diseases, Copenhagen University Hospital – Rigshospitalet, Copenhagen, Denmark*<br>**Catia Marzolini,** *University Hospital Lausanne, Lausanne, Switzerland, and University of Liverpool, Liverpool, UK*<br>**Cristiana Oprea,** *Infectious Diseases, Victor Babes Hospital for Infectious and Tropical Diseases, Bucharest, Romania* | |
| **17:50–18:15** | **Coffee, Exhibition and Scientific Posters** | **Hall 4** |
| **18:15–19:30** | **Industry Symposium** | **Clyde** |

# Tuesday 10 November 2026

| | | |
|---|---|---|
| **08:30–09:45** | **Industry Symposium** | **Clyde** |
| **09:45–10:15** | **Coffee, Exhibition and Scientific Posters** | **Hall 4** |
| **10:15–11:30** | **Novel Strategies and Treatment** | **Clyde** |
| **Chair** | **Claudia P Cortes,** *Infectious Diseases, Universidad de Chile, Santiago, Chile*<br>**Chloe Orkin,** *Queen Mary University of London, and Barts Health NHS Trust, London, UK* | |
| 10:15–10:20 | **Welcome and introduction**<br>**Chloe Orkin** | |
| 10:20–10:40 | **What do the new therapies offer?**<br>**Roy Gulick**, *Division of Infectious Diseases, Weill Cornell Medicine, New York City, NY, USA* | |
| 10:40–10:55 | **New therapies, hard choices: Public health priorities and research gaps**<br>**Alexandra Calmy**, *University of Geneva, Geneva, Switzerland* | |
| 10:55–11:07 | **O31: A 24-week phase 2a maintenance study of TMB-365/TMB-380 q8w in people with suppressed HIV-1 infection**<br>**Martin Markowitz**, *Irving Medical Center, Columbia University, Irvine, CA, USA* | |
| 11:07–11:19 | **O33: Immunogenicity and associated safety of amtabafusp alfa, a bispecific T-cell engager, in a phase 1b study in people with HIV**<br>**Princy Kumar,** *MedStar Georgetown University Hospital, Washington, DC, USA* | |
| 11:19–11:30 | **Close**<br>**Claudia Cortes** | |
| **11:30–12:30** | **Prioritising Young Adults in Efforts to End HIV Transmissions and Improve Quality of Life for All**<br>***In collaboration with the British HIV Association (BHIVA)*** | **Clyde** |
| **Co-chairs** | **Caroline Sabin,** *Institute for Global Health, University College London, London, UK*<br>**Tristan Barber**, *Ian Charleson Day Centre, Royal Free London NHS Foundation Trust, London, UK* | |
| 11:30–11:32 | **Welcome and introduction**<br>**Caroline Sabin** | |
| 11:32–11:42 | **The UK's HIV Action Plan, BHIVA's contribution to this, and next steps for the other devolved nations. Why are young people a crucial group in the country's response to HIV?**<br>**Tristan Barber** | |
| 11:42–11:57 | **How does the HIV Action Plan support young adults?**<br>**Verity Sullivan**, *Axess Sexual Health, University Hospitals of Liverpool Group, Liverpool, UK*<br>**Danny Whitebread,** *London, UK* | |
| 11:57–12:12 | **Addressing issues of specific relevance to young women with vertically acquired HIV, sharing experiences of ways in which clinics have evolved to support this group of women**<br>**Mimie Chirwa,** *Sexual Health and HIV, Bedfordshire NHS Foundation Trust, Luton, UK*<br>**Emma,** *UK* | |
| 12:12–12:27 | **Panel discussion**<br>**All** | |
| 12:27–12:30 | **Close** | |

# Tuesday 10 November 2026

| | | |
|---|---|---|
| **12:30–14:00** | **Lunch, Exhibition and Scientific Posters** | **Hall 4** |
| **12:45–13:45** | **Industry Symposium** | **Clyde** |
| **14:00–14:35** | **Keynote Lecture: Vaccines for HIV and Emerging Viruses**<br>*Joep Lange and Jacqueline van Tongeren Keynote Lecture, dedicated to them in recognition of their commitment and passion to rid the world of HIV/AIDS* | **Clyde** |
| **Chair** | **Linda-Gail Bekker,** *Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa* | |
| 14:00–14:05 | **Welcome and introduction**<br>**Linda-Gail Bekker** | |
| 14:05–14:35 | **Vaccines for HIV and Emerging Viruses**<br>**Robin Shattock,** *Infectious Diseases, Imperial College London, London, UK* | |
| **14:35–15:45** | **Regional Challenges and Solutions Around HIV Access and Implementation** | **Clyde** |
| **Co-chairs** | **Claudia P Cortes,** *Infectious Diseases, Universidad de Chile, Santiago, Chile*<br>**Mitchell Warren**, *AVAC – Global Advocacy for HIV Prevention, New York City, NY, USA* | |
| 14:35–14:50 | **Welcome and setting the scene**<br>**Mitchell Warren** | |
| 14:50–15:20 | **Regional discussants**<br>**Africa: Cissy Kityo,** *Joint Clinical Research Centre, Kampala, Uganda*<br>**Asia Pacific: Iskandar Azwa,** *Infectious Diseases Unit, Faculty of Medicine, University Malaya, Kuala Lumpur, Malaysia*<br>**Europe: Frederico Duarte,** *Infectious Diseases, Hospital Pedro Hispano - ULS de Matosinhos, Matosinhos, Portugal*<br>**Andriy Klepikov,** *Alliance for Public Health, Kyiv, Ukraine, and President-Elect, International AIDS Society*<br>**Latin America: Omar Sued**, *Pan American Health Organization, Washington, DC, WA, USA*<br>**MENA: Roaa Alosaimi,** *HIV Centre of Excellence, East Jeddah Hospital, Jeddah, Saudia Arabia* | |
| 15:20–15:45 | **Panel discussion, Q&A and close**<br>**All** | |
| **15:45–17:25** | **The Hepatitis Alphabet: What's the Latest?** | **Clyde** |
| **Co-chairs** | **Karine Lacombe,** *Hôpital Saint Antoine, Paris, France*<br>**Gilles Wandeler,** *Bern University Hospital, Bern, Switzerland* | |
| 15:45–15:47 | **Welcome and introduction**<br>**Karine Lacombe** | |
| 15:47–16:02 | **Let's not forget about hepatitis A**<br>**Miłosz Parczewski**, *Department of Infectious Diseases, Pomeranian Medical University, Szczecin, Poland and Regional Centre for Digital Medicine, Szczecin, Poland* | |
| 16:02–16:17 | **Hepatitis B 2-drug regimen and re-activation**<br>**Anna-Maria Geretti,** *Royal Free London NHS Trust, London, UK, and University of Rome Tor Vergata, Rome, Italy* | |
| 16:17–16:32 | **Novel treatments for viral hepatitis**<br>**Lisa Sandmann,** *Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany* | |

## Tuesday 10 November 2026

| | | |
|---|---|---|
| **15:45–17:25** | **The Hepatitis Alphabet: What's the Latest? (continued)** | **Clyde** |
| 16:32–16:47 | **Artificial intelligence in cohort studies and clinical trials for chronic viral hepatitis**<br>**Anders Boyd,** *Inselspital, University of Bern, Bern, Switzerland* | |
| 16:47–16:59 | **O34: Isolated hepatitis B core antibody and liver-related outcomes in people living with HIV enrolled in the Swiss HIV Cohort Study**<br>**Adrien Calame,** *Division of Infectious Diseases, Department of Medicine, Geneva University Hospitals and Medical School, Geneva, Switzerland* | |
| 16:59–17:11 | **O35: HBV outcomes after switching to long-acting cabotegravir plus rilpivirine in the Spanish RELATIVITY cohort**<br>**Luz Martín Carbonero,** *HIV Unit, Hospital Universitario La Paz, Madrid, Spain* | |
| 17:11–17:23 | **O36: Hepatitis B after switch to long-acting cabotegravir/rilpivirine: data from the SCohoLART study**<br>**Angelo Roberto Raccagni,** *Infectious Diseases Unit; IRCCS San Raffaele Scientific Institute, Milan, Italy and Vita-Salute San Raffaele University, Milan, Italy* | |
| 17:23–17:25 | **Close**<br>**Gilles Wandeler** | |
| **17:25–17:45** | **Coffee, Exhibition and Scientific Posters** | **Hall 4 Forth Foyer** |
| **17:45–18:30** | **Oral Parallel Session 1: Cardiometabolic Complications** | **Clyde** |
| **Co-chairs** | **Peter Reiss,** *Global Health, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands*<br>**Lene Ryom,** *Centre of Excellence for Health, Immunity and Infections – Rigshospitalet, University of Copenhagen, Copenhagen, Denmark* | |
| 17:45–17:50 | **Welcome and introduction**<br>**Peter Reiss** | |
| 17:50–18:02 | **O37.1: Performance of the SMART2 cardiovascular risk model in people with HIV and prior atherosclerotic cardiovascular disease: a nationwide cohort study in the Netherlands**<br>**Rosa Elias,** *Department of Infectious Diseases, University Medical Centre Utrecht, Utrecht, Netherlands and Department of Internal Medicine, and Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Centre, Rotterdam, Netherlands* | |
| 18:02–18:14 | **O37.2: Statin use for primary prevention of cardiovascular disease among individuals with HIV in the Netherlands, impact of updated (inter)national guidelines**<br>**Colette Smit,** *Stichting HIV Monitoring, Amsterdam, Netherlands and Department of Infectious Diseases, Amsterdam University Medical Center, Amsterdam Institute for Infection and Immunity, Amsterdam, Netherlands* | |
| 18:14–18:26 | **O37.3: T-cell phenotypes and coronary artery disease in people with HIV**<br>**Moisés Alberto Suárez-Zdunek,** *Infectious Diseases, Copenhagen University Hospital – Rigshospitalet, Copenhagen, Denmark* | |
| 18:26–18:30 | **Close**<br>**Lene Ryom** | |

# Tuesday 10 November 2026

| 17:45–18:30 | **Oral Parallel Session 2: Antiretroviral Treatment and Resistance** | **Lomond** |
|---|---|---|
| **Co-chairs** | **Brenda Crabtree-Ramírez,** *Infectious Diseases, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico*<br>**Jonathan Schapiro,** *National Hemophilia Center, Sheba Medical Center, Tel Aviv, Israel* | |
| 17:45–17:50 | **Welcome and introduction**<br>**Jonathan Schapiro** | |
| 17:50–18:02 | **O38.1: Treatment uptake and virological and immunological outcomes of cabotegravir+rilpivirine long-acting therapy versus dolutegravir or bictegravir-based regimens in people living with HIV: RESPOND HIV cohort collaboration**<br>**Alisa Timiryasova,** *Centre of Excellence for Health, Immunity and Infections, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark* | |
| 18:02–18:14 | **O38.2: Long-term effectiveness of long-acting cabotegravir/rilpivirine in people with HIV harboring non-rilpivirine NNRTI resistance mutations: two-year results from the RELATIVITY cohort**<br>**David Rial-Crestelo,** *Hospital Universitario 12 de Octubre, imas12 Health Research Institute, Madrid, Spain and CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain* | |
| 18:14–18:26 | **O38.3: Doravirine susceptibility in people living with HIV with multi-class antiretroviral resistance: a real-world cohort analysis**<br>**Rocio Montejano,** *Hospital Universitario La Paz, IdiPAZ, Madrid, Spain and CIBERINFEC, Madrid, Spain* | |
| 18:26–18:30 | **Close**<br>**Brenda Crabtree-Ramírez** | |
| **17:45–18:30** | **Oral Parallel Session 3: Under-served Populations** | **Forth** |
| **Co-chairs** | **Chloé Pasin,** *SHARE Collaborative, Queen Mary University of London, London, UK*<br>**Romain Palich,** *Immunology and Infectious Diseases, Paris Cité Université, Hôtel-Dieu Hospital, Paris, France* | |
| 17:45–17:50 | **Welcome and introduction**<br>**Chloé Pasin** | |
| 17:50–18:02 | **O39.1: Viral resistance and antiretroviral treatment regimens in French adults with perinatally acquired HIV-1**<br>**Thomas Guilhou,** *Paris Cité University, AP-HP, Hôtel-Dieu Hospital, Immunology and Infectiology Department, Paris, France* | |
| 18:02–18:14 | **O39.2: At the margins of the fringe: intersectional and structural Inequities in HIV testing and healthcare linkage among migrants across 10 European countries – a community-led bio-behavioural cross-sectional study**<br>**Haoyi Wang,** *Department of Work and Social Psychology, Maastricht University, Maastricht, Netherlands and Viroscience Department, Rotterdam, Netherlands* | |
| 18:14–18:26 | **O39.3: Addressing the data gap on recent migrants and HIV: understanding the experiences and long-acting treatment preferences of recent migrants living with HIV from the Ask Us Europe survey**<br>**Megan Devonald,** *Queen Mary University of London, London, UK* | |
| 18:26–18:30 | **Close**<br>**Romain Palich** | |

# Wednesday 11 November 2026

| | | |
|---|---|---|
| **08:30–09:45** | **Women Ageing with HIV: Beyond Viral Suppression Advancing Physical, Mental and Social Health**<br>*In collaboration with the European AIDS Treatment Group (EATG)* | **Clyde** |
| **Co-chairs** | **Aisuluu Bolotbaeva**, *EATG*<br>**Robert James,** *EATG* | |
| 08:30–08:35 | **Welcome and introduction**<br>**Aisuluu Bolotbaeva** and **Robert James** | |
| 08:35–08:45 | **Community perspective**<br>**Memory Sachikonye,** *UK Community Advisory Board – UK-CAB and EATG, London, UK* | |
| 08:45–09:00 | **Co-morbidities and cardiometabolic health**<br>**Shema Tariq,** *University College London, London, UK* | |
| 09:00–09:12 | **Mental health and wellbeing of women ageing with HIV**<br>**Berta Torres,** *Infectious Diseases, Hospital Clinic, Barcelona, Spain* | |
| 09:12–09:24 | **Healthy ageing amongst women with HIV**<br>**Ellen Moseholm,** *Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, Denmark* | |
| 09:24–09:45 | **Panel discussion, Q&A and close**<br>**All faculty**, joined by **Susan Cole-Haley,** *Phoenix Health Movement, London, UK* | |
| **09:45–10:15** | **Coffee, Posters and Exhibition** | **Hall 4** |
| **10:15–11:00** | **Weight Gain in People Living with HIV: A Roundtable Discussion**<br>*In collaboration with The Lancet HIV* | **Clyde** |
| **Chair** | **Peter Hayward,** *The Lancet HIV, London, UK* | |
| 10:15–10:20 | **Welcome and introduction**<br>**Peter Hayward** | |
| 10:20–11:00 | **Reflections on *The Lancet HIV* paper series due to be launched at the Congress**<br>**Jennifer Manne-Goehler,** *Mass General Brigham, Newton, MA, USA*<br>**Nomathemba Chandiwana,** *Desmond Tutu Health Foundation, Cape Town, South Africa* | |
| **11:00–11:02** | **There will be a two-minute silence for Armistice Day** | **SEC** |
| **11:05–12:05** | **When the Money Stops: Navigating Constraints and Protecting Critical Services** | **Clyde** |
| **Co-chairs** | **Angelina Namiba,** *4M Mentor Mothers Network, London, UK*<br>**Alain Volny-Anne,** *Bangkok, Thailand* | |
| 11:05–11:10 | **Welcome and introduction**<br>**Alain Volny-Anne** | |
| 11:10–11:25 | **HIV Treatment: Integrating HIV services in an era of global change**<br>**Joseph Larmarange,** *Institut de Recherche pour le Développement, CEPED, Paris, France* | |
| 11:25–11:35 | **The effects funding cuts/challenges are having on the work of the community**<br>**Magdalena Ankiersztejn-Bartczak,** *Foundation for Social Education, Warsaw, Poland* | |

# Wednesday 11 November 2026

| | | |
|---|---|---|
| **11:05–12:05** | **When the Money Stops: Navigating Constraints and Protecting Critical Services (continued)** | **Clyde** |
| 11:35–11:45 | **The effects funding cuts/challenges are having on the work of the community**<br>**Solange Baptiste,** *International Treatment Preparedness Coalition ITPC) Global, Johannesburg, South Africa* | |
| 11:45–12:05 | **Panel discussion, Q&A and close**<br>**Facilitated by Omar Sued,** *Pan American Health Organization, Washington, DC, USA* | |
| **12:05–12:55** | **Hot Topics and Congress Close** | **Clyde** |
| **Co-chairs** | **Alexandra Calmy,** *University of Geneva, Geneva, Switzerland*<br>**Chloe Orkin,** *Queen Mary University of London, and Barts Health NHS Trust, London, UK* | |
| 12:05–12:10 | **Welcome and introduction**<br>**Alexandra Calmy** | |
| 12:10–12:22 | **O42: Dolutegravir resistance among people with repeated viraemia in a prospective routine HIV care cohort in Lesotho**<br>**Niklaus D Labhardt,** *Department of Clinical Research, University Hospital Basel, Basel, Switzerland* | |
| 12:22–12:34 | **O43: Pharmacokinetics of long-acting injectable cabotegravir in pregnant and postpartum women in South Africa**<br>**Catherine Orrell,** *South Africa Medical Research Centre, Durban / Desmond Tutu Health Foundation, Cape Town, South Africa* | |
| 12:34–12:46 | **O44: Real-world effectiveness of long-acting cabotegravir and rilpivirine in people with HIV-1 subtype A6: preliminary results from the multinational LACRIS study**<br>**Milosz Parczewski,** *Department of Infectious Diseases, Pomeranian Medical University, Szczecin, Poland and Regional Centre for Digital Medicine, Szczecin, Poland* | |
| 12:46–12:55 | **Closing Remarks**<br>**Chloe Orkin** | |
| **12:55–14:00** | **Lunch** | **Forth and Gala Foyers** |

# Oral Abstracts

## Monday 9 November 2026
## Full author lists for Oral Presentations from submitted abstracts

### O21: Higher persistence on twice-yearly lenacapavir versus daily F/TDF for PrEP in the UK and France in the PURPOSE 5 study

Chloe Orkin[1], Jade Ghosn[2], Karine Lacombe[3], Victoria Tittle[4], Killian Quinn[5], Amanda Clarke[6], Gabriel Schembri[7], Patrick Philibert[8], Emily Clarke[9], Hughes Cordel[10], Stephen Taylor[11], Eric Cua[12], Iain Reeves[13], Geoffroy Liegeon[14], Jenna Yager[15], Christoph Carter[15], Yuliang Chen[15], Pamela Wong[15], Moupali Das[15], Jean-Michel Molina[14]
[1]SHARE Collaborative, Blizard Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK. [2]Université Paris Cité, AP-HP, Hôpital Bichat–Claude Bernard, Paris, France. [3]Sorbonne Université, AP-HP, Hôpital Saint-Antoine, Paris, France. [4]Chelsea and Westminster Hospital NHS Foundation Trust, London, UK. [5]Caldecot Centre, King's College Hospital NHS Foundation Trust, London, UK. [6]University Hospitals Sussex NHS Foundation Trust, Brighton, UK. [7]Manchester Centre for Sexual Health, Manchester Royal Infirmary, Manchester, UK. [8]Pôle Multidisciplinaire de Médecine Interne et Maladies Infectieuses, Hôpital Européen, Marseille, France. [9]Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK. [10]Hôpital Avicenne, AP-HP, Bobigny, France. [11]University of Birmingham and Birmingham Heartlands Hospital, Birmingham, UK. [12]University of Nice-Sophia Antipolis, Nice, France. [13]Homerton Healthcare NHS Foundation Trust, London, UK. [14]Université Paris Cité, AP-HP, Hôpital Saint-Louis and Lariboisière, INSERM U944, Paris, France. [15]Gilead Sciences, Inc., Foster City, CA, USA

### O22: Mind the gap: estimating the impact of HIV PrEP on the epidemic in Switzerland

Yuqian Wang[1], Katharina Kusejko[2], Bashkim Jaha[2], Roger Kouyos[1], Vanessa Christinet[3], Florian Vock[4], Dominique Braun[5], Julia Notter[6], Bernard Surial[7], Matthias Cavassini[8], Alexandra Calmy[9], Luigia Elzi[10], Patrick Schmid[11], Irene Abela[2], Andrea Farnham[12], Jan Fehr[12], Benjamin Hampel[12]
[1]Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich,, Zurich, Switzerland. [2]Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland. [3]3Medical Center du Flon, Lausanne, Switzerland. [4]Swiss AIDS Federation, Zurich, Switzerland. [5]Hirslanden Klinik Zurich, Zurich, Switzerland. [6]Division of Infectious Diseases, University Hospital Basel, University of Basel, Basel, Switzerland. [7]Inselspital Bern, University Hospital, University of Bern, Bern, Switzerland. [8]Division of Infectious Diseases, University Hospital Lausanne, University of Lausanne, Lausanne, Switzerland. [9]Division of Infectious Diseases, University Hospital Geneva, University of Geneva, Geneva, Switzerland. [10]Division of Infectious Diseases, Regional Hospital Bellinzona, Bellinzona, Switzerland. [11]Division of Infectious Diseases, Infection Prevention and Travel Medicine, HOCH Health Ostschweiz, Cantonal Hospital St. Gallen (University Teaching and Research Hospital), St.Gallen, Switzerland. [12]Department of Public & Global Health, Epidemiology, University of Zurich Biostatistics and Prevention Institute, Zurich, Switzerland

## Tuesday 10 November 2026
## Full author lists for Oral Presentations from submitted abstracts

### O31: A 24-week phase 2a maintenance study of TMB-365/TMB-380 q8w in people with suppressed HIV-1 infection

Martin Markowitz[1], Jacob P. Lalezari[2], Edwin DeJesus[3], Michael G.Ension[4], Gordon Crofoot[5], Moti Ramgopal[6], Mezgebe Berhe[7], Kuei-Ling Kuo[8], Ying-An Lai[8]
[1]Irving Medical Center, Columbia University, Irvine, CA, USA. [2]Quest Clinical Research, San Francisco, CA, USA. [3]Orlando Immunology Center, Orlando, FL, USA. [4]CAN Community Health, Fort Lauderdale, FL, USA. [5]Crofoot Research Center, Houston, TX, USA. [6]Midway Immunology and Research Center, Fort Pierce, FL, USA. [7]North Texas Infectious Diseases Consultants, Dallas, TX, USA. [8]TaiMed Biologics Inc., Taipei City, Taiwan

### O33: Immunogenicity and associated safety of amtabafusp alfa, a bispecific T-cell engager, in a phase 1b study in people with HIV

Kimberly Workowski[1], Yanan Zheng[2], Xiang Liu[2], Monika Sobczyk[2], Devi SenGupta[2], Elena Vendrame[2], Tina Chakrabarti[2], Princy Kumar[3]
[1]Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA. [2]Gilead Sciences, Inc., Foster City, CA, USA. [3]Division of Infectious Disease, MedStar Georgetown University Hospital, Washington, DC, USA

# Oral Abstracts

**Tuesday 10 November 2026 (continued)**
**Full author lists for Oral Presentations from submitted abstracts**

## O34: Isolated hepatitis B core antibody and liver-related outcomes in people living with HIV enrolled in the Swiss HIV Cohort Study

Adrien Calame[1], Estelle Aymes[2], Lorin Begré[3], Gilles Wandeler[3], Oksana Fiammingo[1], Matthias Cavassini[4], Dominique Braun[5], Alexandra Calmy[1], Maël Barthoulot[2], Olivier Ségéral[1], on behalf of the Swiss HIV Cohort Study
[1]Division of Infectious Diseases, Department of Medicine, Geneva University Hospitals and Medical School, Geneva, Switzerland. [2]Clinical Research Centre, Geneva University Hospital, Geneva, Switzerland. [3]Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. [4]Division of Infectious Diseases, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland. [5]Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland

## O35: HBV outcomes after switching to long-acting cabotegravir plus rilpivirine in the Spanish RELATIVITY cohort

María del Mar Arcos Rueda[1], Miguel Torralba González de Suso[2], Juan Tiraboschi[3], Analuz Fernandez[3], Maria Jose Nuñez Orantos[4], Jesus Troya García[5], Luis Buzón[6], María José Galindo Puerto[7], Ruth Caballero Asensio[8], María Remedios Alemán Valls[9], María Belén Sánchez López[10], Maria Jose Crusells Canales[11], Francisco Fanjul[12], Adrian Rodriguez[13], Maria Carmen Fariñas Álvarez[14], Laura Gisbert Pérez[15], M.Carmen Navarro Sáez[16], Ignacio de los Santos[17], Carmen Hidalgo Tenorio[18], Luis Enrique Morano Amado[19], Enrique Bernal Morell[20], David Vinuesa García[21], Maria Josefa De la Asunción Villaverde[22], Alejandro David Bendala Estrada[23], Luz Martin Carbonero[1], on behalf of RELATIVITY Cohort Group
[1]HIV Unit. Hospital Universitario La Paz, Madrid, Spain. [2]Hospital Universitario Guadalajara, Guadalajara, Spain. [3]Hospital Universitario de Bellvitge, Barcelona, Spain. [4]Hospital Clínico San Carlos, Madrid, Spain. [5]Hospital Universitario Infanta Leonor, Madrid, Spain. [6]Hospital de Burgos, Burgos, Spain. [7]Hospital Clínico Universitario de Valencia, Valencia, Spain. [8]Hospital Universitario Miguel Servet, Zaragoza, Spain. [9]Hospital Universitario de Canarias, Canarias, Spain. [10]Hospital Universitario 12 de Octubre, Madrid, Spain. [11]Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain. [12]Hospital Universitario Son Espases, Mallorca, Spain. [13]Hospital Universitario Son Llatzer (Palma de Mallorca), Mallorca, Spain. [14]Hospital Universitario Marqués de Valdecilla, Santander, Spain. [15]Hospital Universitario Mutua de Terrassa, Barcelona, Spain. [16]Parc Taulí Hospital Universitari, Sabadell, Spain. [17]Hospital Universitario La Princesa, Madrid, Spain. [18]Hospital Universitario Virgen de las Nieves, Granada, Spain. [19]Hospital Universitario Álvaro Cunqueiro, Vigo, Spain. [20]Hospital General Universitario Reina Sofía, Murcia, Spain. [21]Hospital Clínico San Cecilio, Granada, Spain. [22]Hospital de Denia Marina Salud, Alicante, Spain. [23]Hospital Universitario de Torrejón, Madrid, Spain

## O36: Hepatitis B after switch to long-acting cabotegravir/rilpivirine: data from the SCohoLART study

Angelo Roberto Raccagni[1,2], Tommaso Clemente[1], Riccardo Lolatto[1], Nicolò Capra[1], Serena Rolla[1], Hasson Hamid[1], Emanuela Messina[1], Vincenzo Spagnuolo[1,2], Elena Bruzzesi[1], Paola Striglia[1], Silvia Nozza[1,2], Antonella Castagna[1,2]
[1]Infectious Diseases Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy. [2]Vita-Salute San Raffaele, Milan, Italy

## O37.1: Performance of the SMART2 cardiovascular risk model in people with HIV and prior atherosclerotic cardiovascular disease: a nationwide cohort study in the Netherlands

Rosa Elias[1,2], Tessa Reitsma[3], Ferdinand Wit[4,5], Marc van der Valk[4,5], Casper Rokx[2], Annelies Verbon[1], Jannick Dorresteijn[3], Berend van Welzen[1]
[1]Department of Infectious Diseases, University Medical Centre Utrecht, Utrecht, Netherlands. [2]Department of Internal Medicine, and Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Centre, Rotterdam, Netherlands. [3]Department of Vascular Medicine and Endocrinology, University Medical Centre Utrecht, Utrecht, Netherlands. [4]Stichting HIV Monitoring, Amsterdam, Netherlands. [5]Department of Infectious Diseases, Amsterdam Infection and Immunity Institute, I&II, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands

# Oral Abstracts

**Tuesday 10 November 2026 (continued)**
**Full author lists for Oral Presentations from submitted abstracts**

**O37.2: Statin use for primary prevention of cardiovascular disease among individuals with HIV in the Netherlands, impact of updated (inter)national guidelines**

Colette Smit[1,2], Ferdinand Wit[1,2], Dorine de Vries-Sluijs[3], Jan den Hollander[4], Kees Brinkman[5], Berend van Welzen[6], Anna Roukens[7], Wouter Bierman[8], Marc van der Valk[1,2], on behalf of the Athena Observational Cohort
[1]Stichting HIV Monitoring, Amsterdam, Netherlands. [2]Department of Infectious Diseases, Amsterdam University Medical Center, Amsterdam Institute for Infection and Immunity, Amsterdam, Netherlands. [3]Department of Medical Microbiology & Infectious Diseases, Department of Internal Medicine, Erasmus University Medical Centre, Rotterdam, Netherlands. [4]Department of Internal Medicine and Infectious Diseases, Maasstad Ziekenhuis, Rotterdam, Netherlands. [5]Department of Internal Medicine and Infectious Diseases, Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands. [6]Department of Infectious Diseases, University Medical Centre Utrecht, Utrecht, Netherlands. [7]Department of Infectious Diseases, Leiden University Medical Centre, Leiden, Netherlands. [8]Department of Internal Medicine/Infectious Diseases, University Medical Centre Groningen, Groningen, Netherlands

**O37.3: T-cell phenotypes and coronary artery disease in people with HIV**

Hans J. Hansen[1], Moises A. Suarez-Zdunek[1], Dina L. Møller[1], Ask Bock[1], Andreas D. Knudsen[1], Andreas Fuchs[2], Sisse R. Ostrowski[3,4], Thomas L. Benfield[5,4], Klaus F. Kofoed[2,4], Susanne D. Nielsen[1,4]
[1]Department of Infectious Diseases, Copenhagen University Hospital – Rigshospitalet, Copenhagen, Denmark. [2]Department of Cardiology, Copenhagen University Hospital – Rigshospitalet, Copenhagen, Denmark. [3]Department of Clinical Immunology, Copenhagen University Hospital – Rigshospitalet, Copenhagen, Denmark. [4]Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. [5]Department of Infectious Diseases, Copenhagen University Hospital – Amager and Hvidovre, Hvidovre, Denmark

**O38.1: Treatment uptake and virological and immunological outcomes of cabotegravir+rilpivirine long-acting therapy versus dolutegravir or bictegravir-based regimens in people living with HIV: RESPOND HIV cohort collaboration**

Alisa Timiryasova[1], Lauren Greenberg[1], Katharina Kusejko[2,3], Lene Ryom[1,4], on behalf of the RESPOND Study Group
[1]Centre of Excellence for Health, Immunity and Infections, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. [2]Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland. [3]Institute of Medical Virology, University of Zurich, Zurich, Switzerland. [4]Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark

**O38.2: Long-term effectiveness of long-acting cabotegravir/rilpivirine in people with HIV harboring non-rilpivirine NNRTI resistance mutations: two-year results from the RELATIVITY cohort**

David Rial-Crestelo[1,2], Jara Llenas-García[3,2], Carmen Hidalgo-Tenorio[4], Jesús Troya García[5], Noemí Cabello-Clotet[6], María José Galindo Puerto[7], María Remedios Alemán[8], Miguel Torralba González de Suso[9], Luis Buzón[10], Adrián Rodríguez[11], Sonia Calzado Isbert[12], María Aguilera García[13], Luis Enrique Morano Amado[14], David Vinuesa García[15], Enrique Bernal Morell[16], Rosa María Martínez Álvarez[17], Analuz Fernández[18], María del Carmen Montero Hernández[19], Cristina Díez Romero[20], Ruth Calderón Hernáiz[21], Desirée Pérez Martínez[22], Laura Gisbert Pérez[23], Víctor Arenas García[24], Cristina Escrich[25], María Carmen Fariñas Álvarez[26], Ana Lucas Dato[27], Juan Emilio Losa García[28], Hadrián Pernas Pardavila[29], Juan Carlos Gainzarain[30], Miriam Estebánez[31], Patricia Barragán Gallo[32], Marta Clavero Olmos[33], Miguel Vicente Egido Murciano[34], Óscar Luis Ferrero Benéitez[35], Luz Martín-Carbonero[3,2], on behalf of the RELATIVITY Cohort Group

[1]Hospital Universitario 12 de Octubre, imas12 Health Research Institute, Madrid, Spain. [2]CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain. [3]Hospital Universitario La Paz, IdiPAZ Health Research Institute, Madrid, Spain. [4]Hospital Universitario Virgen de las Nieves, Instituto de Investigación Biosanitaria de Granada (IBS-Granada), Granada, Spain. [5]Hospital Universitario Infanta Leonor, Madrid, Spain. [6]Hospital Clínico San Carlos, Madrid, Spain. Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain. [7]Hospital Clínico Universitario de Valencia, Valencia, Spain. [8]Hospital Universitario de Canarias, Tenerife, Spain. [9]Hospital Universitario de Guadalajara, Guadalajara, Spain. [10]Hospital de Burgos, Burgos, Spain. [11]Hospital Universitario Son Llàtzer, Health Research Institute of the Balearic Islands (IdISBa), Palma de Mallorca, Spain. [12]Parc Taulí Hospital Universitari, Sabadell, Spain. Institut d'Investigació i Innovació Parc Taulí (I3PT), Sabadell, Spain. [13]Hospital Universitario de La Princesa, Madrid, Spain. [14]Álvaro Cunqueiro University Hospital, Vigo, Spain. [15]Hospital Clínico San Cecilio-PTS, Granada, Spain. [16]Hospital General Universitario Reina Sofía, Murcia, Spain. [17]Hospital Universitario Miguel Servet, Zaragoza, Spain. [18]Bellvitge University Hospital, Barcelona, Spain. Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain. [19]Hospital Universitario de Torrejón, Madrid, Spain. [20]Hospital General Universitario Gregorio Marañón, Madrid, Spain. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain. [21]Hospital Universitario de Fuenlabrada, Madrid, Spain. [22]Hospital Universitario San Agustín, Avilés, Spain. [23]Hospital Universitario Mutua Terrassa, Barcelona, Spain. [24]Hospital Universitario de Cabueñes, Gijón, Spain. [25]Hospital Verge de la Cinta, Tortosa, Spain. [26]Hospital Universitario Marqués de Valdecilla, Santander, Spain. [27]Hospital Comarcal de la Vega Baja, Alicante, Spain. [28]Hospital Universitario Fundación Alcorcón, Madrid, Spain. [29]Complexo Hospitalario Universitario de Pontevedra, Instituto de Investigación Sanitaria Galicia Sur, Pontevedra, Spain. [30]Hospital Universitario de Álava, Vitoria-Gasteiz, Spain. [31]Hospital Central de la Defensa Gómez Ulla, Madrid, Spain. [32]Hospital Residencia Sant Camil, Barcelona, Spain. [33]Hospital Universitario Infanta Elena, Madrid, Spain. [34]Hospital Universitario San Jorge, Huesca, Spain. [35]Hospital Universitario de Basurto, Bilbao, Spain

**O38.3: Doravirine susceptibility in people living with HIV with multi-class antiretroviral resistance: a real-world cohort analysis**

Alejandro De Gea-Grela[1], Jose I. Bernardino[1], Luz Martin-Carbonero[1], Jara Llenas-Garcia[1], Carmen Busca[1], María Del Mar Arcos-Rueda[1], Rosa De Miguel-Buckley[1], Maria Luisa Montes[1], Rafael Mican[1], Juan Gonzalez-Garcia[1], Jose R. Arribas[1], Rocio Montejano[1,2]

[1]Hospital Universitario La Paz . IdiPAZ, Madrid, Spain. [2]CIBERINFEC, Madrid, Spain

# Oral Abstracts

**Tuesday 10 November 2026 (continued)**
**Full author lists for Oral Presentations from submitted abstracts**

**O39.1: Viral resistance and antiretroviral treatment regimens in French adults with perinatally acquired HIV-1**

Thomas Guilhou[1], Valentine Fihman[2], Patricia Brazille[3], Dominique Batisse[1], Narjis Boukli[4], Clementine De la Porte[1], Claudine Duvivier[5], Marina Karmochkine[1], Odile Launay[6], Alice-Andrée Mariaggi[2], Juliette Pavie[1], Anne Rachline[1], Laurence Slama[1], Jean-Paul Viard[1], Pierre Frange[2], Romain Palich[1]
[1]Paris Cité University, AP-HP, Hôtel-Dieu Hospital, Immunology and Infectiology Department, Paris, France. [2]Paris Cité University, AP-HP, Cochin Hospital, Department of Virology, Paris, France. [3]Paris Cité University, AP-HP, Hôtel-Dieu Hospital, Espace Santé Jeunes, Paris, France. [4]Paris Cité University, AP-HP, Georges-Pompidou European Hospital, Department of Virology, Paris, France. [5]University of Paris Cité, AP-HP, Necker Pasteur Infectiology Centre, Department of Infectious Diseases, Paris, France. [6]Université Paris Cité Inserm, AP-HP, Hôpital Cochin, CIC Cochin Pasteur, Paris, France

**O39.2: At the margins of the fringe: intersectional and structural Inequities in HIV testing and healthcare linkage among migrants across 10 European countries – a community-led bio-behavioural cross-sectional study**

Haoyi Wang[1,2], Hala Majdoub[3], Anne Flaherty-Gupta[3], Kim Isip[4], Pedro Barrios Sanchez[5], Francesco Bellissimo[6], Yiannis Charilaou[7], Christos Krasidis[7], Rosaline M'Bayo[8], Stephen Amoah[8], Trésors Kouadio[9], Robert Ian Kibet Ouko Babu[10], Ann Piercy[11], Abimbola Ajomale[12], Moro Yapha[13], Etinosa Erevbenagie-Johnbull[14], Letonde Hermine Gbedo[15], Kai Jonas[1], Hanne Zimmermann[1], Denis Onyango[3]
[1]Department of Work and Social Psychology, Maastricht University, Maastricht, Netherlands. [2]Viroscience Department, Rotterdam, Netherlands. [3]Africa Advocacy Foundation, London, UK. [4]Association PASTT, Paris, France. [5]Asociacion Karibu, Madrid, Spain. [6]LHIVE Diritti e Prevenzione, Catania, Italy. [7]AIDS Solidarity Movement, Nicosia, Cyprus. [8]Afrikaherz (VIA e.V.), Berlin, Germany. [9]Plateforme Prévention SIDA, Brussels, Belgium. [10]Open Paths Athens, Athens, Greece. [11]HIV Ireland, Dublin, Ireland. [12]Noaks Ark Mosaik, Malmö, Sweden. [13]Fixpunkt e.V., Berlin, Germany. [14]Generation for Change CY, Nicosia, Cyprus. [15]Comitato per i Diritti Civili delle Prostitute, Trieste, Italy

**O39.3: Addressing the data gap on recent migrants and HIV: understanding the experiences and long-acting treatment preferences of recent migrants living with HIV from the Ask Us Europe survey**

Megan Devonald[1], Chloé Pasin[1], Melanie Smuk[1], Rebecca Mbewe[1], Angelina Namiba[2], Marcel Dams[3], Matthew Hodson[4], Nicoletta Policek[5], Alain Volny-Anne[6,7], Luís Mendão[8,9], Magdalena Ankiersztejn-Bartczak[10], Juddy Otti[11], Casper Rokx[12], Frederico Duarte[13], Sophie Strachan[11,1], Marc van der Valk[14], David Jilich[15,16], Bogusz Aksak-Wąs[17], Christophe Rouquette[18], Sarah Brunel[18], Thierry Tran[18], Ann Piercy[19], Simona Saluzzo[20], Chloe Orkin[1], on behalf of Ask Us Steering Group
[1]Queen Mary University of London, London, UK. [2]4M Mentor Mothers, London, UK. [3]Independent Sexual Counselor and Sexual Educator, Berlin, Germany. [4]Independent, London, UK. [5]European Community Led Observatory on Ageing and HIV, Edinburgh, UK. [6]Ask Us Steering Group, Paris, France. [7]EATG, Paris, France. [8]Ask Us Steering Group, Lisbon, Portugal. [9]GAT Portugal, Lisbon, Portugal. [10]Foundation for Social Education, Warsaw, Poland. [11]Sophia Forum, London, UK. [12]Erasmus University Medical Center, Rotterdam, Netherlands. [13]Hospital Pedro Hispano, Matosinhos, Portugal. [14]Amsterdam UMC, Amsterdam, Netherlands. [15]Charles University, Prague, Czechia. [16]University Hospital Bulovka, Prague, Czechia. [17]Pomeranian Medical University, Szczecin, Poland. [18]TRT-5 CHV, Paris, France. [19]HIV Ireland, Dublin, Ireland. [20]Medical University of Vienna, Vienna, Austria

# Oral Abstracts

**Wednesday 11 November 2026**
**Full author lists for Oral Presentations from submitted abstracts**

## O42: Dolutegravir resistance among people with repeated viraemia in a prospective routine HIV care cohort in Lesotho

Anna Klicpera[1], Maren Röhl[1], Blaise Lukau[2], Giuliana Sanchez Samaniego[1], Moleboheng Mokebe[2], Lipontso Motaboli[2], Irene Ayakaka[2], Roger D. Kouyos[3,4], Gioia Wick[3,4], Tom Loosli[3,4], Richard Lessels[5,6], Shirelle Janine Naidoo[6], Jennifer Giandhari[6], Nadine Tschumi[1], Jennifer Anne Brown[1,3], Niklaus D. Labhardt[1]
[1]Department of Clinical Research, University Hospital Basel, Basel, Switzerland. [2]SolidarMed Lesotho, Maseru, Lesotho. [3]Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland. [4]Institute of Medical Virology, University of Zurich, Zurich, Switzerland. [5]Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa. [6]KwaZulu-Natal Research Innovation and Sequencing Platform, University of KwaZulu-Natal, Durban, South Africa

## O43: Pharmacokinetics of long-acting injectable cabotegravir in pregnant and postpartum women in South Africa

Dvora Joseph Davey[1,2], Lauren Jennings[3], Rufaro Mvdudu[3], Chantel Schreuder[3], Elton Mukonda[4], Nyiko Mashele[3], Lubbe Wiesner[4], Landon Myer[4], Saye Khoo[5], Catriona Waitt[5], Linda-Gail Bekker[3], Catherine Orrell[6,3]
[1]Infectious Disease Medicine, Los Angeles, CA, USA. [2]Epidemiology and Biostatistics, Cape Town, South Africa. [3]Desmond Tutu Health Foundation, Cape Town, South Africa. [4]University of Cape Town, Cape Town, South Africa. [5]University of Liverpool, Liverpool, UK. [6]South Africa Medical Research Centre, Durban, South Africa

## O44: Real-world effectiveness of long-acting cabotegravir and rilpivirine in people with HIV-1 subtype A6: preliminary results from the multinational LACRIS study

Miłosz Parczewski[1,2], Aleksandra Szymczak[3], Iwona Cielniak[4,5], Ewa Siwak[4,6], Amelie Berner[7], David Jilich[8], Zuzana A. Lakatošová[8], Wiktor Łukasik[3], Maria Hlebowicz[9], Anita Olczak[10], Bartosz Szetela[3,11], Bogusz Aksak-Was[1], Elżbieta Mularska[12], Paweł Jakubowski[13], Karolina Sorbian-Gajewska[14], Anders Boyd[15,16], Pavel Khaykin[7]
[1]Chair and Department of Infectious Diseases, Pomeranian Medical University, Szczecin, Poland. [2]Regional Centre for Digital Medicine, Szczecin, Poland. [3]All Saint's Clinic, Wrocławskie Centrum Zdrowia SP ZOZ, Wrocław, Poland. [4]Hospital for Infectious Diseases, Warsaw, Poland. [5]Faculty of Medicine, Collegium Medicum, Cardinal Stefan Wyszyński University, Warsaw, Poland. [6]Department of Infectious and Tropical Diseases and Hepatology, Warsaw Medical University, Warsaw, Poland. [7]MainFachArzt, Frankfurt on Main, Germany. [8]Department of Infectious Diseases, 1st, 2nd and 3rd Medical Faculty, Charles University and Faculty Hospital Bulovka, Prague, Czechia. [9]Department of Family Medicine and Infectious Diseases, University of Warmia and Mazury, Olsztyn, Poland. [10]Department of Infectious Diseases and Hepatology, Faculty of Medicine, Ludwik Rydygier Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland. [11]Department of Infectious Diseases, Liver Diseases and Acquired Immune Deficiencies, Wroclaw Medical University, Wrocław, Poland. [12]Department of Infectious Diseases, Regional Hospital Chorzów, Chorzów, Poland. [13]Szpitale Pomorskie, Gdańsk, Poland. [14]Clinical Trials Support Center, Pomeranian Medical University, Szczecin, Poland. [15]Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. [16]Department of Infectious Diseases, Amsterdam Institute for Infection & Immunity (AII) Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands